---
schema_version: "secwatch.filing_event.v1"
accession: "0001808805-21-000004"
form_type: "8-K"
ticker: "NAUT"
cik: "0001808805"
company_name: "Nautilus Biotechnology, Inc."
filed_at: "2021-08-10T23:59:59+00:00"
generated_at: "2026-06-29T17:10:29.345099+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Nautilus Biotechnology Q2 2021 net loss of $10.7M; raised $345.5M in business combination

## Summary
- Completed business combination with ARYA Sciences, receiving gross proceeds of $345.5M.
- Q2 2021 operating expenses $10.7M (up 215% YoY); net loss $10.7M vs $3.4M in Q2 2020.
- Cash and investments $388.4M as of June 30, 2021.
- Appointed Emma Lundberg, Ph.D. to Scientific Advisory Board.
- Planning platform commercialization in late-2023.

## SEC filing metadata
- accession: 0001808805-21-000004
- form_type: 8-K
- ticker: NAUT
- cik: 0001808805
- company_name: Nautilus Biotechnology, Inc.
- filed_at: 2021-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808805/000180880521000004/0001808805-21-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808805/000180880521000004/naut-20210810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001808805-21-000004
- JSON: https://secwatch.observer/filing/0001808805-21-000004.json
- Plain text: https://secwatch.observer/filing/0001808805-21-000004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.